Skip to main content
OpenTrials
Completed

NCT Number: NCT00935311

Hydrocodone/Acetaminophen for Acute Pain Following Third Molar Tooth Extraction

The purpose of this study was to evaluate analgesic efficacy and safety of hydrocodone/acetaminophen compared to placebo in moderate to severe pain following molar extraction.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Site Reference ID/Investigator# 20745, Austin, Texas, United States

Loading trial locations.

About this study

Dosing started within 6 hours after completion of third molar extraction. Study drug was given once every 6 hours for 12 hours (for a total of 2 doses). Participants were randomized to receive placebo or active drug (either experimental drug or comparator). The total dose was the same for both groups receiving active drug, but was given as either 1 dose of extended-release tablets (experimental drug), or 2 doses of immediate-release tablets (active comparator).

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subjects who are in general good health, experiencing moderate to severe pain after surgical extraction of 2 or more third molars and who are willing to remain confined until the morning after surgery for study procedures

Exclusion criteria

  • Allergies to study medications
  • History of multiple drug allergies
  • Unable to stop excluded medications
  • Clinically significant laboratory abnormalities at Screening
  • Significant medical condition at Screening
  • Women who are pregnant or breast feeding

Treatment and study plan

ABT-712 Extended-release

Drug

ABT-712 extended-release tablet

Other names: Hydrocodone/acetaminophen extended-release, Hydrocodone bitartrate and acetaminophen extended-release

Hydrocodone/Acetaminophen Immediate-release

Drug

Hydrocodone/acetaminophen immediate-release tablet

Placebo

Drug

Placebo tablet

Primary outcomes

  1. Sum of Pain Intensity Difference (SPID) Using the Pain Intensity Visual Analog Scale (VAS)

    Time frame: From time of first study drug administration to 12 hours following first study drug administration

    Participants assessed pain intensity on a 100 mm visual analogue scale (VAS) with 0 meaning "no pain" and 100 meaning the "worst pain imaginable". The SPID VAS score for 0 to 12 hours following initial study drug dose measured the cumulative pain intensity difference during treatment with higher mean SPID VAS scores indicating greater improvement from Baseline. The SPID score is a measure of the cumulative pain intensity difference during treatment and the area under the curve was estimated using the linear trapezoidal rule.

Secondary outcomes

  1. TOTPAR (Total Pain Relief)

    Time frame: From time of first study drug administration to 12 hours following first study drug administration

    TOTPAR was the time-interval weighted sum of pain relief. Pain relief was assessed by participants' responses to how their pain relief was compared with the pain they had just before receiving the first dose of study drug: no relief, a little relief, some relief, a lot of relief, or complete relief. Higher mean TOTPAR scores indicate better pain relief. The TOTPAR score is a measure of the cumulative pain intensity difference during treatment and the area under the curve was estimated using the linear trapezoidal rule.

  2. Time to First Rescue Medication

    Time frame: From time of first study drug administration to 12 hours following first study drug administration

    The median time (minutes) from first dose of study drug to first use of analgesic rescue medication.

  3. Participants With Adverse Events (AEs)

    Time frame: AEs were recorded from study drug administration until 30 days following discontinuation of study drug (total 30 days); SAEs were recorded from the time informed consent was obtained until 30 days following discontinuation of study drug (total 51 days).

    An adverse event (AE) is defined as any untoward medical occurrence in a participant, which does not necessarily have a causal relationship with treatment. If an adverse event meets any of the following criteria, it is considered a serious adverse event (SAE): results in death or is life-threatening, results in admission or prolongation of hospitalization, results in congenital anomaly or persistent or significant disability/incapacity, or is an important medical event requiring medical or surgical intervention to prevent serious outcome. AEs were categorized by severity (mild, moderate, severe) and relationship to treatment (probably, possibly, probably not, not related). Please see Adverse Events section below for more details.

Sponsors and collaborators

Lead sponsor

AbbVie (prior sponsor, Abbott)

Industry

Registry information

Official study title

A Randomized, Multicenter, Single-blind, Placebo-controlled Study Comparing the Analgesic Efficacy and Safety of Hydrocodone/ Acetaminophen Extended-release Tablets and Hydrocodone/Acetaminophen (NORCO) to Placebo in Subjects With Acute Pain Following Third Molar Tooth Extraction

Important dates

Study start
2009
Primary completion
2009
Study completion
2009
First posted
Jul 9, 2009
Registry last updated
Apr 8, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.